RSV season starts this week. The AAP just widened who should get a second-season shot.

Editorial context for parents, not medical advice. Talk to your child's clinician before any immunization decision.

The most useful baby-health development of this week is not a recall. It is a timing problem.

In most of the continental United States, RSV monoclonal antibody shots for infants are given from 1 October through 31 March. That window opens in two days. The American Academy of Pediatrics already published its 2026–2027 RSV policy. Pediatric offices and birth hospitals are now trying to match product, age, and risk group before the first wave of bronchiolitis hits.

## Background

Respiratory syncytial virus is still the leading reason previously healthy infants land in hospital with breathing trouble. Until 2023 there was almost nothing for ordinary babies. Palivizumab existed for a small high-risk group and required monthly shots. Then two things arrived: a maternal RSV vaccine given at 32–36 weeks of pregnancy (Pfizer's Abrysvo), and long-acting infant antibodies — nirsevimab first, then clesrovimab.

The design is simple. Either the pregnant parent is vaccinated in that late-pregnancy window, or the baby gets one antibody dose. Most babies do not need both. The antibody lasts about five months, which is roughly one RSV season.

CDC still frames first-season protection that way. AAP still recommends immunization for all infants under 8 months born during or entering their first RSV season unless they have documented protection from a maternal dose.

## What changed

The 2026–2027 AAP policy does not rewrite first-season care. It widens the second-season list.

Children aged 8 through 19 months who are entering their second RSV season and are at high risk should get another dose — regardless of whether the pregnant parent was vaccinated, and regardless of whether the child already received nirsevimab or clesrovimab in year one. Age is chronological, not corrected, for preterm babies.

Groups that were already on the high-risk list include chronic lung disease of prematurity that still needed medical support in the six months before season two, severe immunocompromise, certain cystic fibrosis, and American Indian and Alaska Native children.

AAP added four groups after reviewing hospitalization data:

- born before 32 weeks, whether or not they still need extra support
- hemodynamically significant congenital heart disease
- anatomic lung problems or neuromuscular disorders that raise RSV risk
- Down syndrome or other chromosomal differences with higher severe-RSV risk

Product rules matter. For babies under 8 months, AAP does not prefer nirsevimab over clesrovimab. For the second-season 8–19 month group, only nirsevimab is indicated. Clesrovimab is not approved for that older group. Palivizumab is gone after 31 December 2025.

Timing: October through March in most of the mainland U.S. Tropical climates (Florida, Hawaii, Puerto Rico, Pacific territories) do not follow the same calendar.

## Competing viewpoints

Pediatric infectious-disease groups treat the expansion as catch-up with reality. Preterm babies under 32 weeks and children with significant heart or lung anatomy have always filled RSV wards. The old second-season list left some of them out if they looked "fine" at 9 months.

Public-health agencies that narrowed other pediatric vaccine language this year have been slower and narrower on RSV than AAP. Parents therefore hear two tracks: a pediatric society saying "this toddler is still high risk, give nirsevimab," and a federal page that still emphasizes first-season infants and a shorter high-risk list.

Cost and supply are the other fight. A 200 mg second-season nirsevimab course is two injections. Some insurers still treat second-season doses as optional. Birth hospitals that stock only clesrovimab cannot cover the 8–19 month group at all.

A third view, common in parent forums, is fatigue. Families who already did a maternal shot plus an infant antibody ask why year two exists. The policy answer is blunt: first-season protection wanes, and the newly listed conditions keep hospital risk high in the second winter.

## What to do this week

If your baby is under 8 months and will be in that age band on 1 October, ask whether maternal vaccination already counts as protection. If it does not, ask which antibody the office or birth hospital has on the shelf.

If your child is 8–19 months and has any of the conditions above — including birth before 32 weeks with no current oxygen — ask specifically about a second-season nirsevimab dose. Do not assume last year's shot still covers this winter.

If you are 32–36 weeks pregnant in RSV season, ask whether Abrysvo is available this visit. Most infants then skip the antibody unless they are in a special-risk group.

Check your state's season start if you live in the South or a territory. October 1 is not universal.

## What to watch next

- Whether commercial plans and Medicaid treat the four new second-season groups as covered without prior authorization.
- Whether nirsevimab supply reaches pediatric clinics, not only nurseries.
- Early-season hospitalization data for the newly included groups.
- Any CDC language change that either matches or undercuts AAP on second-season eligibility.

Sources: AAP policy and technical report on RSV prevention in infants and children, 2026–2027; HealthyChildren.org summary dated 1 September 2026; CDC infant RSV immunization pages; Contemporary Pediatrics recap 28 September 2026.

This is editorial context for parents, not a recommendation for any individual child.